Aoife Brennan - 10 Nov 2023 Form 4 Insider Report for SYNLOGIC, INC. (SYBX)

Reporting relationship: President and CEO, Director
Issuer ticker: SYBX
Reported as of: 10 Nov 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Nov 2023, 19:23:02 UTC
Prior SEC filing: 09 Jun 2023
Next SEC filing: 06 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Aoife Brennan

Key filing fact

Aoife Brennan filed Form 4 for SYNLOGIC, INC. (SYBX) on 14 Nov 2023.

Key facts

This page summarizes Aoife Brennan's Form 4 filing for SYNLOGIC, INC. (SYBX).
20 reported transactions and 20 derivative rows are listed below.
Accepted by SEC: 14 Nov 2023, 19:23.

Change

Previous filing in this sequence was filed on 09 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SYBX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -5,591
Change %: -100%
Price
Shares after: 0
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,591
Exercise price: $202.95
Footnotes: F1, F2

SYBX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -3,733
Change %: -100%
Price
Shares after: 0
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,733
Exercise price: $149.25
Footnotes: F1, F2

SYBX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -3,600
Change %: -100%
Price
Shares after: 0
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,600
Exercise price: $143.25
Footnotes: F1, F2

SYBX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -9,999
Change %: -100%
Price
Shares after: 0
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,999
Exercise price: $118.65
Footnotes: F1, F2

SYBX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -12,332
Change %: -100%
Price
Shares after: 0
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,332
Exercise price: $128.85
Footnotes: F1, F2

SYBX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -12,352
Change %: -100%
Price
Shares after: 0
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,352
Exercise price: $25.50
Footnotes: F1, F3

SYBX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -18,999
Change %: -100%
Price
Shares after: 0
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,999
Exercise price: $52.50
Footnotes: F1, F4

SYBX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -28,943
Change %: -100%
Price
Shares after: 0
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 28,943
Exercise price: $29.25
Footnotes: F1, F5

SYBX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -42,999
Change %: -100%
Price
Shares after: 0
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 42,999
Exercise price: $9.30
Footnotes: F1, F6

SYBX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -8,666
Change %: -100%
Price
Shares after: 0
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,666
Exercise price: $9.30
Footnotes: F1, F7

SYBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +5,591
Change %
Price
Shares after: 5,591
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,591
Exercise price: $1.85
Footnotes: F1, F2

SYBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +3,733
Change %
Price
Shares after: 3,733
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,733
Exercise price: $1.85
Footnotes: F1, F2

SYBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +3,600
Change %
Price
Shares after: 3,600
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,600
Exercise price: $1.85
Footnotes: F1, F2

SYBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +9,999
Change %
Price
Shares after: 9,999
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,999
Exercise price: $1.85
Footnotes: F1, F2

SYBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +12,332
Change %
Price
Shares after: 12,332
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,332
Exercise price: $1.85
Footnotes: F1, F2

SYBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +12,352
Change %
Price
Shares after: 12,352
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,352
Exercise price: $1.85
Footnotes: F1, F3

SYBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +18,999
Change %
Price
Shares after: 18,999
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,999
Exercise price: $1.85
Footnotes: F1, F4

SYBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +28,943
Change %
Price
Shares after: 28,943
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 28,943
Exercise price: $1.85
Footnotes: F1, F5

SYBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +42,999
Change %
Price
Shares after: 42,999
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 42,999
Exercise price: $1.85
Footnotes: F1, F6

SYBX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +8,666
Change %
Price
Shares after: 8,666
Date: 10 Nov 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,666
Exercise price: $1.85
Footnotes: F1, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.

Footnote F2

The shares subject to this option are fully vested as of the date hereof.

Footnote F3

The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2020 through April 1, 2024.

Footnote F4

The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2021 through April 1, 2025.

Footnote F5

The shares subject to this option vest in approximately equal monthly installments beginning on February 4, 2022 through February 4, 2026.

Footnote F6

The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027.

Footnote F7

These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met.